Kind of a milquetoast quarter, however not a bit disappointing
Sales up from last year. Biovance developed. Recent acquisition. This stock will probably start to make a run especially considering the real meat of the sales force hasn't been on the job but for a couple months. Celgene was one of the underwriters of that last offering? People should probably dismiss ALQA now at their own peril..